AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02372318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT00287677
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART all over the trial
Trial: NCT00003088
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given IV
Trial: NCT00003088
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given IV
Trial: NCT02944981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT04255407
Drug: Anti-inflammatory drug
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain before and after ACL reconstruction will be managed with common anti-inflammatory drugs (Paracetamol)
Trial: NCT01440569
Drug: DRV
RxNorm normalized name: Urinal Male Drv RTLPC23201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg (2 x 400 mg tablets) administered orally with food once daily
Trial: NCT01440569
Drug: NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.
Trial: NCT01490697
Drug: Placebo-matching d-Cycloserine (DCS)
RxNorm normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo-matching DCS capsules
Trial: NCT01270906
Drug: CHIR-258 (TKI258)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00923169
Drug: Anti-Transforming Growth Factor-beta (GC 1008)
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01636726
Drug: Inhaled LABA use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
Trial: NCT00488267
Drug: ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch applied to the knee for 12 hours daily.
Trial: NCT00488267
Drug: Placebo Matrix/CHADD Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch applied to the knee for 12 hours daily.
Trial: NCT00488267
Drug: Ketoprofen matrix/placebo CHADD Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal knee applied to the knee for 12 hours daily.
Trial: NCT03953079
Drug: Drug: GB-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of GB-102
Trial: NCT01966679
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01966679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00379808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 lactose-containing capsule daily for 1 month
Trial: NCT01432561
Drug: Cysteamine bitartrate
RxNorm normalized name: Cysteamine Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg total, single dose taken orally on visits 2, 3 \& 4 which must occur within a 14 day period.
Trial: NCT00129181
Drug: carbidopa/levodopa
RxNorm normalized name: CARBIDOPA/LEVODOPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
Trial: NCT02214095
Drug: glucosamine sulphate
RxNorm normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
Trial: NCT02214095
Drug: lactose capsules
RxNorm normalized name: lactose Oral Capsule
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00546325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets. Once daily before breakfast
Trial: NCT02860117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo continuous infusion (0,2 ml/kg/h)
Trial: NCT01813513
Drug: IDX719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tablet for oral administration
Trial: NCT01659658
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide tablets
Trial: NCT02291549
Drug: S8 Sinus Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
Trial: NCT00919815
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisolone 40mg daily then reducing regimen over 24 weeks
Trial: NCT01489683
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
Trial: NCT01763307
Drug: RECONVAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01763307
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01780428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00515892
Drug: Immunotoxin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02312258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib placebo-matching capsules.
Trial: NCT00004401
Drug: botulism immune globulin
RxNorm normalized name: botulism immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02570672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will randomized to placebo will receive placebo
Trial: NCT02852122
Drug: C-11 choline
RxNorm normalized name: choline C-11
DrugBank: Choline C-11 (DB09563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA \> 20 ng/mL, or Gleason score 8-10, or clinical stage \>T2c) would be included.
Trial: NCT02556437
Drug: Subcuvia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human immunoglobulin 16% for subcutaneous injection
Trial: NCT02287350
Drug: diclofenac potassium oral solution
RxNorm normalized name: diclofenac potassium Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
Trial: NCT01303120
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled analgesia with morphine
Trial: NCT04322786
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any prescription of ACE inhibitor
Trial: NCT02912455
Drug: Placebo (for canagliflozin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.
Trial: NCT00915915
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
Trial: NCT00915915
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
Trial: NCT01845337
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00130026
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg IV
Trial: NCT04505202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients included in the placebo group ( sodium bicarbonate) will receive 3 times daily oral care
Trial: NCT03725033
Drug: Subetta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT03725033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT00649363
Drug: Zofran ODT® Tablets 8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8mg, single dose fasting
Trial: NCT02237235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.
Trial: NCT00336843
Drug: Zevalin-BuCyE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rituximab (IV, 250 mg/m2 on days -21 and -14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day -14) Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5) Cyclophosphamide (IV, 50 mg/kg on days -3 and -2) Etoposide (IV, 200 mg/m2 every 12 h on days -5 and -4) Autologous stem cells infusion on day 0
Trial: NCT04294251
Drug: DWP450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A(DWP450) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
Trial: NCT04294251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo(Normal Saline) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
Trial: NCT04192656
Drug: Ginaton
RxNorm normalized name: Genaton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ginnaton is ginkgo biloba extract
Trial: NCT02690519
Drug: GLPG1837 dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
Trial: NCT02690519
Drug: GLPG1837 dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
Trial: NCT02352987
Drug: Neem plus propylene glycol plus salicylic acid
RxNorm normalized name: propylene glycol salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
Trial: NCT02450552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT02710305
Drug: oral placebo tablets plus placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
Trial: NCT02412904
Drug: HMG
RxNorm normalized name: HMG-CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
Trial: NCT00835328
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.
Trial: NCT01288092
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00770133
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of vehicle ophthalmic solution at visit 3 and visit 4.
Trial: NCT01142193
Drug: USL255
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03396484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral dosing
Trial: NCT00649051
Drug: Zaroloxyn® Tablets 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4x2.5mg, single dose fasting
Trial: NCT01554176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one tablet, orally, once daily at bedtime
Trial: NCT02664922
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
Trial: NCT01134601
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01492686
Drug: MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Trial: NCT01492686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Trial: NCT00079638
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00079638
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03244462
Drug: BAY1834845
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose (IR \[immediate release\] tablets)
Trial: NCT03244462
Drug: BAY1834845
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.v. infusion of \[13C6\]-labeled BAY1834845
Trial: NCT00981747
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.
Trial: NCT02678000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of LHW090
Trial: NCT02604173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill and sham inhaler
Trial: NCT00691873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02153229
Drug: Photofrin 2.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
Trial: NCT00223730
Drug: Citrulline
RxNorm normalized name: Citrulline
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
Trial: NCT00223730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00741585
Drug: Any antihypertensive medication alone or in combination
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All drugs on awakening
Trial: NCT00741585
Drug: Any antihypertensive medication alone or in combination
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or more drugs at bedtime
Trial: NCT00308321
Drug: long term tapering of prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
Trial: NCT00308321
Drug: standard prednisolone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
Trial: NCT00388297
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
Trial: NCT00388297
Drug: Placebo for Levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02507843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered in placebo group monthly for 6 months.
Trial: NCT04478500
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase.
Trial: NCT00648505
Drug: Metaglip® Tablets 5 mg/500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5/500mg, single dose fed
Trial: NCT03126864
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 900 mg/m2 administered by vein on Day -3.
Trial: NCT03114657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Trial: NCT00396877
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight
Trial: NCT03531892
Drug: AJM300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AJM300 film-coated tablets.
Trial: NCT03531892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to AJM300 tablets.
Trial: NCT01858909
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration via oral or via a nasogastric tube followed by 20mL saline
Trial: NCT04086342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a vehicle oil that will match CHI-902.
Trial: NCT04023266
Drug: Intravenous N-Acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.
Trial: NCT01295567
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prior to CABG surgery 3 day treatment with placebo capsules twice daily
Trial: NCT02470403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT00704548
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin once daily, orally in the morning period, during eigth weeks
Trial: NCT00704548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily, orally in the morning period, during eigth weeks
Trial: NCT02329301
Drug: Focal MDA with DHAp (Eurartesim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurartesim is the brand name.
Trial: NCT01078051
Drug: optimal medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: optimal medical therapy
Trial: NCT02607657
Drug: Eplerenone 25 mg
RxNorm normalized name: eplerenone 25 MG
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02607657
Drug: Eplerenone 50 mg
RxNorm normalized name: eplerenone 50 MG
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02607657
Drug: Eplerenone 100 mg
RxNorm normalized name: eplerenone 100 MG
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02607657
Drug: Eplerenone 50 mg twice a day
RxNorm normalized name: eplerenone 50 MG
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02607657
Drug: Eplerenone 25 mg twice a day
RxNorm normalized name: eplerenone 25 MG
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no